Sarepta Therapeutics' low P/S ratio reflects its poor revenu...

Sarepta Therapeutics' low P/S ratio reflects its poor revenue outlook. The market anticipates limited growth, hence the reduced stock price. Even a recent share price surge couldn't bring the P/S to industry median. A strong share price rise seems unlikely under these conditions.